drugset / Trial / NCT00786734

Pitavastatin Pre-Treatment Study in Patient With Elective PCI for Stable Angina Pectoris (PIPA)

NCT00786734

Phase 4 Withdrawn JW Pharmaceutical
RandomizedParallel-groupOpen-labelPrevention

Summary

Patients who is scheduled elective PCI are randomized to pitavastatin 4mg daily or without pitavastatin for 5 -7days before the procedure. Creatine kinase-MB, troponin I, and myoglobin levels are measured at baseline and at 8 and 24 hours after the procedure(1st evaluation). After PCI, pitavastatin will be administered for additional 4 weeks(2nd evaluation).

Timeline

Start
2008-08
Primary completion
2009-05
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Pitavastatin Small molecule 4 mg

Indications

No indication recorded.